Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OPK
stocks logo

OPK

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
158.98M
-8.42%
--
--
160.45M
-12.61%
--
--
154.18M
+2.85%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for OPKO Health, Inc. (OPK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -12.50%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-12.50%
In Past 3 Month
5 Analyst Rating
up Image0
Wall Street analysts forecast OPK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPK is 3.36 USD with a low forecast of 2.25 USD and a high forecast of 5.20  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 1.190
sliders
Low
2.25
Averages
3.36
High
5.20
up Image0
Current: 1.190
sliders
Low
2.25
Averages
3.36
High
5.20
JPMorgan
Neutral
initiated
2025-04-25
Reason
JPMorgan
Price Target
2025-04-25
initiated
Neutral
Reason
JPMorgan initiated coverage of Opko Health with a Neutral rating and no price target. Following a series of asset sales and monetizing transactions, Opko is closing in on its goal of becoming a self-funded biotech company, the analyst tells investors in a research note. However, the firm believes it will take a series of clinical wins to gain broader investor recognition, with shares likely to trade range-bound over the mid-term.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-04-07
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-04-07
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-03-19
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-03-19
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-03-12
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-03-12
Reiterates
Strong Buy
Reason
Barrington Research
Michael Petusky
Buy
Maintains
$2.25
2025-03-12
Reason
Barrington Research
Michael Petusky
Price Target
$2.25
2025-03-12
Maintains
Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-03-03
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-03-03
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for OPKO Health Inc (OPK.O) is -5.95, compared to its 5-year average forward P/E of 85.68. For a more detailed relative valuation and DCF analysis to assess OPKO Health Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
85.68
Current PE
-5.95
Overvalued PE
444.96
Undervalued PE
-273.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-17.79
Current EV/EBITDA
-24.80
Overvalued EV/EBITDA
20.81
Undervalued EV/EBITDA
-56.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
1.71
Current PS
1.58
Overvalued PS
2.10
Undervalued PS
1.31

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1498.79% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

OPK News & Events

Events Timeline

(ET)
2025-06-25
08:06:40
Opko Health, Entera Bio say OPK-88006 data selected for ENDO 2025
select
2025-06-09 (ET)
2025-06-09
08:18:53
Opko Health's ModeX forms Scientific Advisory Board
select
2025-04-04 (ET)
2025-04-04
08:08:13
Opko Health board authorizes $100M increase to existing share repurchase program
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.5
08-01NASDAQ.COM
PinnedCompared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics

  • OPKO Health Financial Performance: OPKO Health reported a revenue of $156.8 million for Q2 2025, marking a 13.9% decline year-over-year and falling short of the Zacks Consensus Estimate by 5.09%. The EPS was -$0.19, significantly worse than the expected -$0.12.

  • Investment Opportunities: Zacks Investment Research offers stock recommendations through private portfolios, highlighting past successes with substantial gains, encouraging investors to access their insights for potential profits.

Preview
4.0
08-01NASDAQ.COM
Validea Kenneth Fisher Strategy Daily Upgrade Report - 8/1/2025

  • Stock Ratings Update: Validea's Price/Sales Investor model, based on Kenneth Fisher's strategy, has upgraded ratings for several stocks including FTI Consulting (FCN) from 58% to 80%, OPKO Health (OPK) from 48% to 60%, Limoneira Co (LMNR) from 58% to 70%, Vimeo Inc (VMEO) from 58% to 70%, and Zevia PBC (ZVIA) from 48% to 60%, indicating varying levels of interest based on their fundamentals and valuations.

  • Company Descriptions: The article provides insights into the operations and segments of each company, highlighting FTI Consulting's advisory services, OPKO Health's biopharmaceuticals and diagnostics, Limoneira's agribusiness activities, Vimeo's video platform solutions, and Zevia's zero-sugar beverage offerings.

Preview
7.0
08-01SeekingAlpha
OPKO Health outlines $640M–$660M 2025 revenue target as BioReference sale and pipeline advances drive profitability push

  • Management Insights: OPKO Health is focusing on strategic initiatives, including the sale of BioReference's oncology business to Labcorp, which aims to enhance financial performance and operational focus. The company reported progress in its pharmaceutical pipeline and anticipates significant cost savings while aiming for cash flow breakeven in 2025.

  • Financial Performance: In Q2 2025, OPKO Health experienced a net loss of $148.4 million, attributed largely to a convertible note exchange expense. Despite this, management remains optimistic about future growth driven by pipeline advancements and regulatory approvals, while adjusting revenue guidance downward for the year.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is OPKO Health Inc (OPK) stock price today?

The current price of OPK is 1.19 USD — it has decreased -7.03 % in the last trading day.

arrow icon

What is OPKO Health Inc (OPK)'s business?

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

arrow icon

What is the price predicton of OPK Stock?

Wall Street analysts forecast OPK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPK is 3.36 USD with a low forecast of 2.25 USD and a high forecast of 5.20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is OPKO Health Inc (OPK)'s revenue for the last quarter?

OPKO Health Inc revenue for the last quarter amounts to 156.81M USD, decreased -13.93 % YoY.

arrow icon

What is OPKO Health Inc (OPK)'s earnings per share (EPS) for the last quarter?

OPKO Health Inc. EPS for the last quarter amounts to -0.19 USD, increased 1800.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for OPKO Health Inc (OPK)'s fundamentals?

The market is revising No Change the revenue expectations for OPKO Health, Inc. (OPK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -12.50%.
arrow icon

How many employees does OPKO Health Inc (OPK). have?

OPKO Health Inc (OPK) has 2997 emplpoyees as of August 03 2025.

arrow icon

What is OPKO Health Inc (OPK) market cap?

Today OPK has the market capitalization of 944.60M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free